LATEST NEWS
December 10, 2014 | Company Announcements
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate CancerDecember 04, 2014 | Company Announcements
Bavarian Nordic Announces First Subject Dosed with MVA-BN® Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines November 30, 2014 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/S